Examining Representation Disparities in aRCC Clinical Trials
July 4, 2023
A recently published abstract in the Journal of Clinical Oncology examined patient populations in clinical trials for advanced renal cell carcinoma (aRCC), finding that significant underrepresentation based on age, ethnicity, and racial backgrounds. The study examined data from multiple real-world evidence (RWE) and randomized controlled trials (RCTs) covering over 4800 patients.
According to Brooke McCormick, “As for race and ethnicity, Black patients accounted for 17.2% in RWE, 1.6% in RCT, and 4.8% in SEER data. Asian patients accounted for 6.3%, 11.8%, and 6.0%, respectively, and Hispanic patients accounted for 15.0%, 3.4%, and 19.7%. From these results, researchers discovered that Hispanic patients were better represented within RWE studies than RCT studies (15.0% vs 3.4%; P < .001). White patients were the best-represented group as they accounted for 71.7% in RWE, 84.5% in RCT, and 67.5% in SEER data.”
To read more, click here.
(Source: AJMC, July 3rd, 2023)
